{
    "clinical_study": {
        "@rank": "92492", 
        "arm_group": [
            {
                "arm_group_label": "Part A: DKN-01  (Dose Escalation)", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15, and 80 milligrams per meter squared of body surface area (mg/m2) of Paclitaxel administered on days 1,8,15, and 22"
            }, 
            {
                "arm_group_label": "Part B: DKN-01 (Dose Confirmation)", 
                "arm_group_type": "Experimental", 
                "description": "Dose of DKN-01 determined in Part A will be administered on Days 1 and 15, and 80 mg/m2 of Paclitaxel administered on Days 1,8,15,and 22"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the safety and tolerability of DKN-01 in combination with weekly\n      paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal\n      junction cancer"
        }, 
        "brief_title": "A Study of DKN-01 in Combination With Paclitaxel", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Esophageal Neoplasms", 
            "Adenocarcinoma of the Gastroesophageal Junction", 
            "Gastroesophageal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Neoplasms", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal\n      Cancer or Gastro-Esophageal Junction Tumors. Part B is an Expansion Cohort in Participants\n      with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  In advanced esophageal malignancies:\n\n               -  Participants with histologically confirmed recurrent or metastatic esophageal or\n                  gastro-esophageal junction squamous cell or adenocarcinoma whose tumors express\n                  Dkk-1 by immunohistochemistry (IHC)\n\n               -  Participants must be refractory or intolerant to at least one prior standard\n                  therapy(ies) for metastatic or locally advanced disease\n\n                    1. If prior therapy consisted of palliative chemoradiation therapy it will be\n                       considered one line of therapy\n\n                    2. Prior treatment with paclitaxel as part of a definitive therapy regimen is\n                       acceptable provided the patient is not intolerant of paclitaxel\n\n          -  Must have one or more tumors measurable on radiographic imaging as defined by the\n             Response Evaluation Criteria in Solid Tumors (RECIST)\n\n          -  Must be ambulatory\n\n          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.\n             A performance status of 2 on the ECOG scale may be entered upon the review and\n             approval of the medical monitor\n\n          -  Have an estimated life expectancy of at least 3 months, in the judgment of the\n             investigator\n\n          -  Disease-free of active second/secondary or prior malignancies for equal to or over 2\n             years with the exception of currently treated basal cell, squamous cell carcinoma of\n             the skin, or carcinoma \"in-situ\" of the cervix or breast\n\n          -  Acceptable liver function of:\n\n               1. Bilirubin less than or equal to (\u2264) 1.5 times upper limit of normal (ULN)\n\n               2. Aspartate aminotransferase (AST)(SGOT), alanine aminotransferase (ALT)(SGPT),\n                  gamma-glutamyl transferase (GGT) and alkaline phosphatase \u2264 2.5 times upper\n                  limit of normal (if liver metastases are present, then \u2264 5 x ULN is allowed)\n\n          -  Acceptable renal function with calculated creatinine clearance greater than or equal\n             to (\u2265) 50 mL/min using the Cockcroft and Gault Method\n\n          -  Acceptable hematologic status of:\n\n               1. Granulocyte \u2265 1500 cells/mm3\n\n               2. Hemoglobin \u2265 9 g/dL (transfusion permitted within 30 days of study entry)\n\n               3. Platelet count \u2265 100,000 (plt/mm3)\n\n          -  Acceptable coagulation status:\n\n               1. Prothrombin time/partial thromboplastin time (PT/PTT) \u2264 1.2 x ULN (unless\n                  receiving anticoagulation therapy, if receiving anticoagulation therapy,\n                  eligibility will be based upon the international normalised ratio(INR) as\n                  follows):\n\n               2. INR \u2264 1.6 (unless receiving anticoagulation therapy). If receiving warfarin: INR\n                  \u2264 3.0 and no active bleeding, (i.e., no bleeding within 14 days prior to first\n                  dose of study therapy)\n\n          -  For men and women of child-producing potential, the use of effective contraceptive\n             methods during the study and for 6 months following the last dose of study drug Women\n             of child-bearing potential and men must agree to use adequate contraception (hormonal\n             or barrier method of birth control) during the study, and must agree to use adequate\n             contraception prior to study entry and for 6 months after their last dose of study\n             drug. Should a woman become pregnant or suspect she is pregnant while participating\n             in this study, she should inform her treating physician immediately\n\n        Exclusion Criteria:\n\n          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction\n             within the past 6months, unstable arrhythmia\n\n          -  Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 (male), or\n             history of congenital long QT syndrome. Any ECG abnormality that in the opinion of\n             the investigator would preclude safe participation in the study\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study\n             entry requiring systemic therapy\n\n          -  Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface\n             antigen (HBSAg), or hepatitis C antibodies (HCAb)\n\n          -  History of major organ transplant (for example: heart, lungs, liver and kidney)\n\n          -  History of autologous or allogenic bone marrow transplant\n\n          -  Serious nonmalignant disease that could compromise protocol objectives in the opinion\n             of the investigator and/or the sponsor\n\n          -  Pregnant or nursing women\n\n          -  History of osteonecrosis of the hip or have evidence of structural bone abnormalities\n             in the proximal femur on MRI scan that are symptomatic and clinically significant.\n             Degenerative changes of the hip joint are not exclusionary. Screening of asymptomatic\n             participants is not required.\n\n          -  Symptomatic central nervous system (CNS) malignancy or metastasis. Participants with\n             treated CNS metastases are eligible provided their disease is radiographically\n             stable, asymptomatic, and they are not currently receiving corticosteroids and/or\n             anticonvulsants. Radiation must have been completed at least 14 days prior to study\n             entry. Screening of asymptomatic participants without a history of CNS metastases is\n             not required\n\n          -  Clinically significant peripheral neuropathy at the time of registration\n\n          -  Known osteoblastic bony metastasis. Screening of asymptomatic participants without a\n             history of metastatic bony lesions is not required\n\n          -  Treatment with surgery or chemotherapy within 28 days prior to study entry (42 days\n             for nitrosoureas or mitomycin C)\n\n          -  Participants who are currently receiving any other investigational agent or have\n             received an investigational agent within last 30 days or 5 half-lives, whichever is\n             longer\n\n          -  Previously treated with an anti-Dkk-1 therapy\n\n          -  Participants who have a history of hypersensitivity reactions to TAXOL\u00ae or other\n             drugs formulated in Cremophor\u00ae EL (polyoxyethylated castor oil)\n\n          -  Significant allergy to a pharmaceutical therapy that, in the opinion of the\n             investigator, poses an increased risk to the participant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013154", 
            "org_study_id": "DEK-Dkk1-P102", 
            "secondary_id": [
                "DKN-01", 
                "LY2812176"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A: DKN-01  (Dose Escalation)", 
                    "Part B: DKN-01 (Dose Confirmation)"
                ], 
                "description": "Administered by IV infusion before Paclitaxel", 
                "intervention_name": "DKN-01", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A: DKN-01  (Dose Escalation)", 
                    "Part B: DKN-01 (Dose Confirmation)"
                ], 
                "description": "Administered by IV infusion", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Janet Murphy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08903"
                    }, 
                    "name": "Rutgers Cancer Institute of New Jersey"
                }, 
                "investigator": {
                    "last_name": "Rebecca Moss, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Balazs Halmos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "John Strickler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology / Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Johanna Bendell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University / VICC"
                }, 
                "investigator": {
                    "last_name": "Jordan Berlin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "CTRC @ The University of Texas Health Science Center at San Antonio"
                }, 
                "investigator": {
                    "last_name": "Deva Mahalingam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Two Part, Phase 1, Multi-Center, Open-Label Study of DKN-01 in Combination With Weekly Paclitaxel in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors", 
        "overall_contact": {
            "email": "Dekkun@Choruspharma.com", 
            "last_name": "Dekkun Corporation"
        }, 
        "overall_official": {
            "affiliation": "Dekkun Corporation", 
            "last_name": "Email Dekkun@Choruspharma.com", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose Determined According to Incidence of Dose-Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to end of cycle (approximately 4 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 3 months)"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 3 months)"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 3 months)"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 3 months)"
            }, 
            {
                "measure": "Summary Statistics of DKN-01 Serum Concentrations", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 1 pre-dose to Cycle 2 Day 1 pre-dose (approximately 4 weeks)"
            }
        ], 
        "source": "Dekkun Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dekkun Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}